Pyrrolylquinoxalinediones: Dicarboxylates as highly potent AMPA receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 19, 1997, Pages 2441-2446

  Lubisch, W ^a   Behl, B ^b   Hofmann, H P ^b   Teschendorf, H J ^b  

^a BASF SE   (Germany)

^b Knoll AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 2,3 QUINOXALINEDIONE DERIVATIVE; 6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; GLUTAMATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONVULSION; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; RECEPTOR AFFINITY;

EID: 0030868167     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)00428-9     Document Type: Article

References (32)

1. a) D.W. Choi, Sem. in Neurosci. 1994, 6, 127-132;
2. b) M.D. Ginsberg, K. Takagi and M.Y.T. Globus in J.Krieglstein and H. Oberpichler-Schwenk (Ed.), Pharmacology of Cerebral Ischemia 1992, 177-189.
3. W. Danysz, C.G. Parsons, I. Bresing and G. Quarck, Drugs, News & Perspectives 1995, 8, 261-277;
4. b) K.W. Muir and K.R. Lees, Stroke 1995, 26, 503-513;
5. c) A.M. Buchan, H. Lesiunk, K.A. Barnes, Hui Li, Z.G. Huang, K.E. Smith and D. Xue, Stroke 1993, 24, Suppl. I, 148-152.
6. M.J. Sheardown, E.O. Nielsen, A.J. Hansen, P. Jacobsen and T. Honoré, Science 1990, 247, 571-574.
7. a) M.D.B. Swedberg, P. Jacobsen and T. Honoré, J. Pharmacol.Exp.Ther., 1995, 274, 1113-1121;
8. b) T. Namba, K. Morimoto, K. Sato, N. Yamada and S. Kuroda, Brain Res., 1994, 638, 36-44.
9. a) J. Ohmori, S. Sakamoto, H. Kuboto, M. Shimizu-Sasamata, M. Okada, S. Kawasaki, K. Hidaka, J. Togami, T. Furuya and K. Murase, J. Med. Chem. 1994, 37, 467-475.
10. a) T.C. Malone, F. Wätjen, C.F. Bigge, L.H. Jensen, P.A. Boxer and L.J. Lescosky, Abstr.Pap.Am.Chem.Soc., 207 Meet., Pt. 1 Medi 179, 1994;
11. b) F. Wätjen, C.F. Bigge, L.H. Jensen, P.A Boxer, L.J. Lescosky, E. O. Nielsen, T.C. Malone, G.W. Campbell, L.L. Coughenour, D.M. Rock, J. Drejer, F.W. Marcoux, Bioorg. Med. Chem. Lett. 1994, 4, 371-376.
12. R. Bullock, D.I. Graham, S. Swanson and J. McCulloch. J. Cerebral Blood Flow Metabol. 1994, 14, 466-471.
13. C.F. Bigge, T.C. Malone, P.A. Boxer, C.B. Nelson, D.F. Ortwine, R.M. Schelkun, D.M. Retz, L.J. Lescosky, S.A. Borosky, M.G. Vartanian, R.D. Schwarz, G.W. Campbell, L.J. Robichaud and F. Wätjen, J.Med.Chem. 1995, 38, 3720-3740.
14. a) P. Morain, P. Lestage, A. Roger, C. Bobichon, P. Desos, A.A. Cordi and J. Lepagnol, Br. J. Pharmacol. 114, Proc.Suppl., 330P, 1995;
15. b) P. Desos, J.M. Lepagnol, P. Morain, P. Lestage and A.A. Cordi, J. Med. Chem. 1996, 39, 197-206.
16. S.E. Smith and B.S. Meldrum, Stroke 1992, 23, 861-864.
17. W. Lubisch, B. Behl and H.P. Hofmann, Bioorg. Med. Chem. Lett. 1996, 6, 2887-2892.
18. W. Lubisch, B. Behl and H.P. Hofmann, Bioorg. Med. Chem. Lett. 1997, 7, 1101-1106.
19. D.J. Sam and H.F. Simmons, J.Am.Chem.Soc. 1972, 94, 4024-4027.
20. T. Honoré, S.N. Davies, J. Drejer, E.J. Fletscher, P. Jacobsen, D. Lodge and F.E. Nielsen, Science 1988, 241, 701-703.
21. a) J.C.R. Randle, T. Guet, C. Bobichon, C. Moreau, P. Curutchet, B. Lambolez, L. Prado DeCarvallo, A.A. Cordi and J.M. Lepagnol, Mol. Pharmacol. 1992, 337-345;
22. b) A.A. Cordi, P. Desos, J.C.R. Randle and J. Lepagnol, Bioorg. Med. Chem. Lett. 1995, 3, 129-141.
23. T. Honoré, J. Drejer and M. Nielsen, Neurosci. Lett. 1986, 65, 47-52.
24. L. Dalgaard, R.K. Hjortkjaer and L. Nordholm, Drug Metab. Disp., 1994, 22, 289-293.
25. a) C.P. Taylor and M.G. Vartanian, Eur.J.Pharmacol. 1992, 213, 151-3;
26. b) T. Zarnowski, Z. Kleinrok, W.A. Turski and S.J. Czuczwar, Neuropharmacology, 1993, 32, 895-900.
27. The determination of log Pow's were performed according an established HPLC-method: OECD-test guidelines 107, Paris 1981, Decision of Council C(81) -30-Final-HPLC-method.
28. K.T. Hansen, Biochem. Pharmacol. 1995, 49, 489-493. R.M. Woodward, J.E. Huettner, M. Tran, J. Guastella, J.F. Keana and E. Weber, J.Pharmacol.Exp.Ther. 1995, 275, 1209-1218.
29. K.T. Hansen, Biochem. Pharmacol. 1995, 49, 489-493. R.M. Woodward, J.E. Huettner, M. Tran, J. Guastella, J.F. Keana and E. Weber, J.Pharmacol.Exp.Ther. 1995, 275, 1209-1218.
30. L. Dagaard, R.K. Hjotkjaer, B. Regnier and L. Nordholm, Drug Metab.Disp. 1994, 22, 289-293.
31. S.J. Hays, P.A. Boxer, C.P. Taylor, M.G. Vartanian, L.J. Robichaud and E.O. Nielson, Bioorg. Med. Chem. Lett. 1993, 3, 77-80.
32. S.E. Smith, N. Dürmüller and B.S. Meldrum, Eur.J.Pharmacol. 1991, 201, 179-183.